Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Company Performance - Vir Biotechnology reported a quarterly loss of $1.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.7, representing an earnings surprise of -67.14% [1] - The company posted revenues of $0.24 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 96.59%, compared to revenues of $2.38 million in the same quarter last year [2] - Over the last four quarters, Vir Biotechnology has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during this period [2] Stock Performance - Shares of Vir Biotechnology have declined approximately 28.5% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.64 on revenues of $5.59 million, while for the current fiscal year, the estimate is -$3.11 on revenues of $15.09 million [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is currently in the top 40% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]